Relay Therapeutics (RLAY) Common Equity (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Common Equity data on file, last reported at $642.2 million in Q1 2026.

• On a quarterly basis, Common Equity fell 10.94% year-over-year to $642.2 million in Q1 2026; TTM through Mar 2026 was $642.2 million, a 10.94% decrease from a year earlier, with the FY2025 full-year figure at $567.1 million, down 27.09% from the prior year.
• Common Equity for Q1 2026 stood at $642.2 million, up from $567.1 million in the prior quarter.
• Over the last five years, Common Equity for RLAY reached as high as $999.8 million in Q3 2022 and fell as low as $567.1 million in Q4 2025.
• Historically, Common Equity has averaged $767.3 million across 5 years, with a median of $777.8 million in 2024.
• Across the five-year window, Common Equity jumped 75.06% in 2022 and declined 27.56% in 2025, its largest moves.
• Year by year, Common Equity stood at $950.2 million in 2022, then fell by 20.86% to $752.0 million in 2023, then rose by 3.43% to $777.8 million in 2024, then dropped by 27.09% to $567.1 million in 2025, then rose by 13.25% to $642.2 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $642.2 million in Q1 2026, $567.1 million in Q4 2025, and $607.7 million in Q3 2025.